Printer Friendly

SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG

    SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
    TOKYO, Nov. 21 /PRNewswire/ -- Secom Co., Ltd. (Capital 35.9 billion yen, President Kenichi Komine) through its subsidiary Tecno-Bio Co., Ltd. (Capital 24 million yen, President Takashi Nakamura) concluded a joint R and D agreement to develop a new anti-cancer drug with Harrier Inc. (Capital 756,000 dollars, President Jurg Kehrli), a Swiss American venture listed on NASDAQ and the Boston Stock Exchange.
    Tecno-Bio Co., Ltd., from its establishment in 1988, has been engaged in developing "diesel cleaner" (50 percent NOX reduction device by water-fuel emulsion), water purification apparatus and CO2 absorption system.  It is the policy of Secom that all revenue from this project shall be invested for further R and D and that for the time being Secom shall not have any contribution to its business result.
    This project is aimed at synthesizing and commercializing glycoside of a substance which is expected to have anti-cancer effect, "Tumosterone" a reproduction of a naturally-occurring substance in the thymus gland of the body that is believed to inhibit the growth of cancerous tumors through the body's immune system.  This radical new type of anti-cancer drug, "Tumosterone" which is expected to have fewer side effects because of its natural origins, had been under development by Dr. Klemke since 1988.
    Biological testing has begun at the Cancer Therapy and Research Center Institute of Drug Development in San Antonio, Texas, to confirm prior research on the product.  It is currently being tested against mammary tumor and melanoma cells, both highly virulent forms of cancer in humans.
    Since the method by which this glycoside is produced has broad applicability to other drugs, Harrier has entered into an agreement with the University of Michigan, Department of Chemistry, to verify its theoretical mechanism.
    Tumosterone was invested by Dr. Klemke of Germany, and its production method (Klemke Method) is called "glycosylation."  This is a chemical reaction by which a carbohydrate is attached to an organic molecule and is an area of intensive interest among practicing organic and medical chemists.
    The Klemke Method, compared to current technology, is a process by which such a reaction is produced more mildly, effectively and at a lower cost than presently available glycosylation methods.  It is expected to be widely applicable to drugs currently on the market as well as to drugs still under development.
    Secom, as a financially strong stockholder holding 13.9 percent of Harrier's shares, will support this joint R and D project through its Tecno-Bio subsidiary with the objective of developing with Harrier this unique drug and production method of glycoside.  The first phase of verification tests are scheduled to be completed at the University of Michigan before the end of the current year, after which efforts will be actively undertaken to license this technology.
    -0-              11/21/91 R
    /CONTACT:  Hitoshi Morimoto of Secom Co., Ltd., in Japan, 03-3348-5215/ CO:  Secom Co., Ltd.; Harrier Inc.; Tecno-Bio Co., Ltd. ST: IN:  MTC SU:  JVN TS -- NY121R -- 6211 11/22/91 07:19 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1991
Words:507
Previous Article:SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
Next Article:TUFF STUFF PUBLISHING, INC. TO PRODUCE AND DISTRIBUTE TRADING CARDS FEATURING THE PEANUTS COMIC STRIP CHARACTERS
Topics:


Related Articles
HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN; ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY
GOVERNMENT CONTRACT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO FORMULATE CANCER AND AIDS DRUGS
IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC
HARRIER ESTABLISHES BIOCHEMICAL SUBSIDIARY
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
HARRIER PLANS IND SUBMISSION
HARRIER ANNOUNCES FAVORABLE TEST RESULTS
HARRIER TERMINATES AGREEMENT WITH AMERICAN DIAGNOSTICA INC.
Phytomedics and SK Chemicals Life Science R&D Center Enter Botanical Drug Collaboration.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters